ClinicalTrials.gg
CompletedNCT00362687Updated Mar 31, 2009

GMB: Study of Truvada (TDF+FTC) or Emtricitabine (FTC) Alone Versus HAART Interruption in HIV-Infected Patients With Resistance

A Phase 4 interventional study of Truvada (TDF+FTC) alone and FTC alone in HIV Infections, sponsored by Gilead Sciences. Completed at 1 site in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-31.

Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing emtricitabine in HIV Infections — 4 open to participants now, 8 under way, 4 of them phase 3. Emtricitabine · HIV Infections.

Enrollment
41st of 63
50 · median 100
Started
2006
with 3 others
Phase 4
22 of 65
3 open now
Registered
19th of 65
by date
Lead sponsor
14 of 65
Gilead Sciences

Among the 65 studies testing emtricitabine in HIV Infections, this one is the 41st largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2006, is one of 22 in phase 4, and was the 19th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

4 of the 65 studies testing emtricitabine in HIV Infections are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About emtricitabine

Emtricitabine: first FDA approval 2003 (EMTRIVA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing emtricitabine in HIV Infections, or all of them as a file.
02

Study summary

Many patients who already harbor drug-resistant HIV require interruption of HAART due to poor compliance, poor quality of life, toxicity or development of resistance. In these patients interruption of HAART has a negative impact on patient immune status due to the reemergence of wild-type virus which is in general more pathogenic than HIV isolates containing resistance mutations. There is a need for "bridging" antiretroviral regimens that might prolong time off conventional HAART whilst waiting for a new regimen that is either fully suppressive or less toxic or less demanding for the patient.

Read the detailed description

Virological failure associated with the appearance of resistant mutations is still common in patients receiving HAART. When HAART fails patients and clinicians can chose from three different courses of action:

  1. Switch therapy to a new salvage regimen based on the results of resistance testing.

    Success of the new salvage regimen is maximized if the new regimen includes antiretroviral drugs without cross-resistance with previous failed drugs or, preferably,new classes of drugs. In general, rescue regimens are more complicated for patients due to its higher pill burden; more frequent dosing and sometimes need for parenteral therapy (Enfuvirtide).

  2. Stop therapy. This strategy is feasible in patient with relatively preserved immune function. Time off antiretroviral therapy would be highly dependent on previous nadir CD4 cell count (the lowest the nadir, the more rapidly patients loses CD4 cells). In patients with multidrug resistant virus this strategy is used with the goal of achieving virus reversion towards wild-type forms. Reversion towards wild-type virus would theoretically "resensitize" HIV to prior failed drugs. Unfortunately, a number of investigations have suggested that the loss of CD4 cell count occurred during the time off therapy might not be regained after starting rescue therapy. In addition, reversion towards wild type virus does not appear to be associated with a more favourable outcome of rescue therapy.
  3. Maintain failing therapy. This strategy has the potential advantage of decreasing the rate of CD4 cell loss. It is known that certain mutations of HIV decrease viral fitness and produce a less pathogenic virus. Consequently, compared to wild-type virus, CD4 destruction is decreased in the presence of resistance mutations. The very important risk inherent to this strategy is the accumulation of new antiretroviral mutations if the regimen is maintained. Due to cross-resistance among antiretroviral drugs, accumulation of new mutations decreases the chances of success of a new salvage regimen.

Choosing among these three different strategies depends on a number of important factors.

  1. Availability of antiretroviral drugs active against resistant HIV isolates. Clinicians would be more prone to switch to a new salvage regimen if the new regimen contains a new class of drugs and/or at least three drugs without cross resistance with the antiretroviral included in the failing regimen. This scenario is very likely after first or second regimen failure. However, after third regimen failure the possibilities of including at least three active drugs dramatically decrease. For deep salvage the possibilities of constructing a viable rescue regimen often depends on enrolling the patient in a clinical trial of a new antiretroviral (for example CCR5 inhibitors). Enrolment in the trial very often implies that patients have to wait for an undefined period of time until the trial starts.
  2. Willingness of patient to switch to a more complicated regimen. After second regimen failure, rescue therapies involve a higher pill burden, more frequent dosing and, in a substantial number of cases, the need of parenteral therapy with enfuvirtide. In this situation it is possible that the patient prefer not to start the new therapy due to the negative impact of the new regimen in his quality of life.
  3. Immune status of the patient. In patients with low CD4 cell count stopping therapy can put the patient at risk of developing an opportunistic disease. In general patients and clinicians are reluctant to stop therapy if the current CD4 cell count is below 200-250 cells/mL.

Apart from the setting of virological failure HAART interruption might be needed in patients with well controlled viral replication (HIV viremia persistently below 50 copies/ mL). Possible reasons for HAART interruption in this scenario are:

  1. Toxicity of current regimen.
  2. Patient desire (for example travel abroad).
  3. Poor quality of life related to treatment issues.
  4. Poor adherence to current HAART regimen and an impending risk of developing resistance mutations. When a patient stop HAART due to these reasons, wild-type HIV re-emerges with the consequent loss of CD4 cells. Depending on the immune status of the patient and prior CD4 cell nadir time off therapy might be quite limited.
03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • HIV, HAART
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-1 infection documented by confirmed positive HIV-1 antibody test and/or positive PCR for HIV-1 RNA.

  • Adult patients (over 18 years of age).
  • Available genotype (current or historical) showing M184V and (≥ 2 TAMs or K65R).
  • ≥ 350 cells/mL.
  • Patient request HAART interruption due to any of the following:

    1. Patient is receiving a suppressive HAART regimen but has problems with adherence,quality of life or toxicity AND there is no alternative simpler, less toxic regimen (typically patients with substantial resistance and good virological control while receiving multiple antiretrovirals).
    2. Due to resistance, patient is receiving a non-suppressive HAART regimen but patient is not willing to change to a new, already available, more complicated optimized salvage regimen (typically 3rd or 4th ).
  • For women of , negative urine pregnancy test at screening visit.
  • Agreement to take part in the study and sign the .

Exclusion criteria

Exclusion Criteria:

Patients receiving a non-registered antiretroviral (ARV) drug.

  • Patients who have \< 50 -RNA copies/mL while receiving an NNRTI.
  • Serum positive and patient is receiving an anti-HBV active nucleoside/nucleotide.
  • to one of the components of the dosage forms of TDF or FTC, or previous history of intolerance to one of these drugs.
  • Known history of drug abuse or chronic alcohol consumption that in the clinician opinion contraindicates participation in the study.
  • Women who are pregnant or breast feeding or females of who do not use an adequate method of according to the investigator's judgment.
  • Current active opportunistic infection or documented infection within the previous 4 weeks.
  • Documented active malignant disease (excluding Kaposi sarcoma limited to the skin).
  • Renal disease with \< 50 mL/min.
  • Concomitant use of nephrotoxic or immuno-suppressive drugs (should be stopped prior to enrollment)
  • Receiving on-going therapy with systemic , Interleukin-2 (IL-2) or chemotherapy.
  • Patients who are not to be included in the study according to the investigator's criterion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    1

    Truvada 1 tablet once a day.

    Drug: Truvada (TDF+FTC) alone · Procedure: No HAART

  • Experimental
    2

    Emtricitabine 1 capsule once a day

    Drug: FTC alone · Procedure: No HAART

Interventions

  • DrugTruvada (TDF+FTC) alone

    tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation

  • emtricitabine 200 mg

  • ProcedureNo HAART

    No HAART

06

What researchers measure

Primary outcomes

  1. To compare CD4 cell loses 24 weeks after HAART discontinuation

    Time frame: Through 48 weeks

Secondary outcomes

  1. Proportion of patients with re-initiation of HAART within 24 and 48 weeks

    Time frame: Through 48 weeks

  2. To compare CD4 cell loses 48 weeks after HAART discontinuation

    Time frame: Through 48 weeks

  3. To compare HIV viral loads 4, 24 and 48 weeks after HAART discontinuation:time-weighted average change from baseline through 24 and 48 weeks (DAVG24 and DAVG48) for log10 plasma HIV-1 RNA for patients with plasma HIV-1 RNA >50 copies/mL at baseline

    Time frame: Through 48 weeks

  4. To compare HIV viral loads 4, 24 and 48 weeks after HAART discontinuation: time-weighted average change from 4 weeks through 24 and 48 weeks (DAVG24 and DAVG48) for log10 plasma HIV-1 RNA for patients with <50 copies/mL at baseline

    Time frame: Through 48 weeks

  5. To compare HIV viral loads 4, 24 and 48 weeks after HAART discontinuation: proportion of patients with HIV RNA <400 and <50 copies/mL at 4 weeks for subjects with plasma HIV-1 RNA <50 copies/mL at baseline

    Time frame: Through 48 weeks

  6. To compare HIV viral loads 4, 24 and 48 weeks after HAART discontinuation: compare log10 plasma HIV-1 RNA at week 4 for patients with HIV-RNA < 50 copies/mL at baseline.

    Time frame: Through 48 weeks

  7. To compare development of new mutations in the reverse transcriptase gene 24 and 48 weeks after HAART discontinuation.

    Time frame: Through 48 weeks

  8. Proportion of patients with any adverse event.

    Time frame: Through 48 weeks

  9. Proportion of patients for each adverse event.

    Time frame: Through 48 weeks

  10. Distribution of the intensity if each adverse event (the greatest intensity for each adverse event within a patient will be considered).

    Time frame: Through 48 weeks

  11. Distribution of the relationship between the adverse effect and the study drug (the strongest relation with the study drug for each adverse event within each patient will be considered).

    Time frame: Through 48 weeks

  12. Proportion of patients who discontinue the study prematurely (before week 48)due to adverse events.

    Time frame: Through 48 weeks

  13. Changes in patient's quality of life analyses.

    Time frame: Through 48 weeks

07

Study locations

1 site
  • Gilead Sciences, S.L.
    Madrid, E-28036, Spain
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2006, a primary completion of May 2008 and a completion of Oct 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2006
First posted
Aug 10, 2006
Start
Nov 2006
Primary completionActual
May 2008
CompletionActual
Oct 2008
Last update
Mar 31, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 31, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00362687
Lead sponsor
Gilead Sciences
First posted
Aug 10, 2006
Start date
Nov 2006
Primary completion
May 2008
Completion
Oct 2008
Last update
Mar 31, 2009

Study contacts

Pedro Ferrer
study director · Gilead Sciences, S.L.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Emtricitabine

Start the discussion